We have a proprietary cancer biology platform that has allowed us to develop our clinical-stage drug candidates and several additional preclinical-stage drug candidates in potentially important areas. These currently consist of potential targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.
As an innovative biotechnology company with research facilities in China, we have been able to attract an internationally-trained research team of more than 600 talented scientists. The team has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort.
Immunotherapy has now been established as one of the cornerstones of anticancer treatments. There is tremendous potential for synergistic combinations of cancer immunotherapies and also for combining cancer immunotherapies with targeted therapies. Our preclinical pipeline consists of additional targeted therapies and immuno-oncology agents.
Evaluating Potential Combinations
To evaluate the potential different combinations, we are using our extensive collection of in vitro, in vivo and ex vivo cancer models. These proprietary models developed in house have elements of a functional immune system integrated through allogeneic, syngeneic and humanization methods.